Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary

Abeona Therapeutics reported treating 12 patients since launching its treatment, with 4 of those treatments recognized for revenue in Q2 2026 due to manufacturing variability. The company reached its target of 7 qualified treatment centers (QTCs) by year-end, including prominent sites like Cincinnati Children's Hospital and Children's Hospital of Philadelphia (CHOP).

However, the 84-hour shelf life of their product, ZEVASKYN, presents operational challenges, requiring precise coordination among various medical professionals. Two patients had to cancel their biopsies at the last minute, unable to be rescheduled due to the extensive pre-planning needed for surgical slots.

Manufacturing yields are currently at 9 sheets per lot, which is higher than the clinical trial averages but a low-yield batch fell below the 4-sheet revenue recognition threshold. Abeona is shifting its focus to reporting completed treatments and recognized revenue instead of scheduled biopsies, acknowledging the unpredictability of the latter. The company anticipates a steady-state cadence of about 1 patient per month per QTC once they surpass the initial learning curve.

The CMS granted Abeona New Technology Add-on Payment (NTAP) status starting October 1, 2026, which management believes will improve access for Medicare patients. Additionally, Abeona is collaborating with the FDA to revise the specifications for their Pan-CK identity test following a batch failure during the BLA review. Management expects clinical validation to gain momentum as early adopters share positive real-world outcomes through peer-to-peer discussions.

The financial strategy aims for a sustainable cash-flow-positive model by maintaining a consistent treatment cadence and utilizing a relatively stable manufacturing cost base.

One batch was deemed out of specification due to a new identity test not used in clinical trials, but the patient was still treated without revenue recognition. Q2 gross margins stood at 63%, but management anticipates normalized margins of 85% to 90% as volumes expand and fixed costs are better absorbed. R&D expenses saw a significant decrease quarter-over-quarter following a one-time in-licensing cost of $7 million for ABO-701 in Q1 2026.

The company holds a cash reserve of $146.8 million as of June 30, 2026, to support the ongoing commercial rollout. Management emphasized that despite a single low-yield batch, commercial batches currently average 9 sheets, significantly higher than the 5-sheet average observed in Phase III trials. Although Medicare accounts for just 10% of the payer mix, NTAP provides a crucial mechanism to prevent financial losses for high-cost innovative therapies at hospitals.